A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
ConditionIgG4-Related Diseases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorLuo Yaping
About this trial
This study intends to use the new technology of fibroblast activation protein PET / CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET / CT are related to the recurrence of IgG4-RD in patients with IgG4-RD who have been clinically evaluated for complete remission after treatment.
Eligibility criteria
Qualifiers
age 18-75 years old ;
Meet the 2019 ACR / EURLAR IgG4-RD diagnostic criteria ;
The disease was stable for more than 1 year, and the clinical evaluation of the disease was complete remission * ;
Glucocorticoid dosage ≤ prednisone 7.5mg / d × 6 months or more, or combined with an immunosuppressive therapy ( mycophenolate mofetil ) Ester ≤ 1.0g / d, leflunomide ≤ 20mg / d, methotrexate ≤ 15mg / w, azathioprine ≤ 100mg / d, iguratimod ≤ 25mg Bid )
Disqualifiers
None
Trial design
Treatments tested in this trial
- 68Ga-FAPI PET / CT
Treatment groups
46 Participants
are divided into 2 treatment groupsSponsors and collaborators
Luo Yaping
Lead sponsor
Peking Union Medical College Hospital
Sponsor institution
Peking Union Medical College Hospital
Collaborator
Source ClinicalTrials.gov